Collins Pushed for Insulin Price Cap Vote
Senator Susan Collins urged a Senate vote on a bipartisan insulin cost-limiting bill ahead of the November election.
Updated on Sept. 25, 2026 in Legislative Policy
Live Poll
Should federal lawmakers prioritize capping insulin costs before other legislative business?
Senator Susan Collins is advocating for a floor vote on her bipartisan legislation that would cap monthly insulin costs at $35 for those with private, employer-sponsored insurance. However, Senate leadership has not scheduled the measure, prioritizing other business before members depart for the campaign trail.
Why it matters
Proponents argue that the legislation would provide critical financial relief to a large sector of the population struggling with high medication costs. Senate leadership has limited time remaining in the current session, leaving the bill's prospects uncertain.
The bill, which passed the Senate Health, Education, Labor and Pensions Committee by a 17-5 vote, includes a pilot program to cap insulin costs for uninsured individuals in 10 states. It aims to set a $35 monthly price cap for individuals with private insurance.
The players
Susan Collins
Susan Collins is a United States Senator from Maine who serves on the Senate Health, Education, Labor and Pensions Committee.
John Thune
John Thune serves as the Senate Majority Leader and determines the legislative agenda for the chamber.
The details
Lawmakers are currently debating potential strategies to advance the legislation, including the possibility of attaching it to must-pass measures like the National Defense Authorization Act. This push comes as attention in the Senate remains focused on other legislative priorities, such as a framework for college athletics.
Timeline
In July 2026, the Senate committee approved the bill with a 17-5 vote.
During the week of September 20, 2026, the Senate debated a national framework for college athletics.
The November 2026 midterm elections serve as the deadline for the current legislative session.
Political Context
Opposition to the insulin bill's expedited passage centers on the Senate's packed legislative schedule, which currently prioritizes the Ratepayer Protection Act. Dissenting leaders emphasize that limited floor time must be reserved for must-pass legislation rather than individual healthcare proposals.
The potential passage of this bill would impact monthly out-of-pocket costs for residents with private, employer-sponsored insurance by capping their insulin expenses at $35. Additionally, the proposed pilot program could expand price protections to uninsured individuals across 10 states.
The takeaway
The struggle to pass this insulin price cap highlights the difficulty of moving targeted healthcare legislation during the final weeks of an election-year session. Voters may see insurance coverage trends, such as the 10% decline in Maine ACA participation, become central talking points for future policy.
Further reading
Learn more about the current legislative status of healthcare reforms in the Legislative Policy section.
Live Poll
Should federal lawmakers prioritize capping insulin costs before other legislative business?
